Seeking Alpha EN

Burning Rock Biotech GAAP EPS of -$0.02, revenue of $18.1M

Mar 12, 2026 &03451212202631; 19:45 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -35/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Burning Rock Biotech reported a GAAP loss per share of -$0.02 with quarterly revenue of $18.1M, indicating continued operational losses despite revenue generation. The company remains unprofitable on a GAAP basis, though revenue figures suggest ongoing business activity in the biotech sector.

AI CONFIDENCE

65% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

BRK

BRKStock

Expected to decline

Negative EPS and continued GAAP losses signal profitability challenges despite revenue generation

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Monitor cash burn rate and path to profitability closely. Consider waiting for positive EPS or significant revenue acceleration before initiating long positions; current losses warrant caution despite revenue presence.

KEY SIGNALS

Negative GAAP EPS of -$0.02Revenue of $18.1M indicates operational activityContinued unprofitability raises sustainability concernsBiotech sector volatility and cash burn trajectory

SECTORS INVOLVED

BiotechnologyHealthcare

Analysis generated on Mar 16, 2026 at 16:26 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Burning Rock Biotech GAAP EPS of -$0.02, revenue of $18.1M

RELATED INTELLIGENCE